We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
Jennifer Caudle, DO
Sara A. Hurvitz, MD, FACP
Narjust Florez, MD
The Oncogenic Significance – and Promise – of HER3 in Pharmacotherapy
Helena Yu, MD
Makenzi Evangelist, MD
Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer
Hope S. Rugo, MD, FASCO
Peter Schmid, FRCP, MD, PhD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education